Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 7, 2010

View Archived Issues

Roche discovers new inverse agonists of GABA(A) alpha5 receptor

Merck KGaA divulges novel inhibitors of protein kinases

Preliminary efficacy reported in first-in-human trial of LFB-R603 in chronic lymphocytic leukemia

Interim data from phase I trial of PF-03732010 in advanced solid tumors reveal good tolerability

Oncolytic prodrug BMS-817378 selected for clinical development

Activity seen with ARRY-520 in patients with relapsed/refractory multiple myeloma

ACT Biotech describes activity of Aurora kinase inhibitor ACTB-1010

Phase II results for plitidepsin in peripheral T-cell lymphoma presented

The Leukemia and Lymphoma Society provides support to BioTheryX

Case Western Reserve University licenses insulin analogues to Thermalin Diabetes

MorphoSys and Xencor start phase I study of MOR-208 in chronic lymphocytic leukemia

Cell Therapeutics appeals FDA decision on pixantrone NDA for non-Hodgkin's lymphoma

Cyrenaic reports results from phase IIa CYR-101 trial in schizophrenia

Agios Pharmaceuticals describes novel pyruvate kinase M2 activators

Insmed and Transave enter into business combination

Geron begins phase II imetelstat trial in breast cancer

Forest Laboratories discloses novel acetyl-CoA carboxylase inhibitors

New antibacterials created by UMDNJ and Rutgers scientists

BioMarin receives U.K. approval for clinical trial of BMN-673 in genetically defined cancers

Cynapsus reports data for Parkinson's drug candidate APL-130277

QR Pharma cleared to conduct clinical trials with bisnorcymserine for AD

Long-term phase III study confirms efficacy of avanafil for erectile dysfunction

Prochieve 8% reduces incidence of preterm birth in phase III study

FDA accepts for review sBLA for subcutaneous Orencia

Pfizer plans 2011 regulatory submissions for bosutinib in CML

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...